Glenmark Pharmaceuticals Ltd announced that its subsidiary, Glenmark Specialty S A (GSSA), has entered into a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), a cancer treatment drug. Under the agreement, Glenmark gains the license for KN035 (Envafolimab) in various regions, including India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America.
